Last updated: February 9, 2026
Overview
NDC 33342-0243 is a medication marketed by Novartis, identified as Ruxolitinib (brand name Jakafi). It is primarily used for myelofibrosis, polycythemia vera, and graft-versus-host disease. The drug's market landscape is shaped by clinical demand, regulatory status, pricing policies, and competitive dynamics.
Market Size and Demand
The global myelofibrosis and polycythemia vera markets are expanding, driven by increased diagnoses and adoption. In 2022, the US market for Jakafi generated approximately $1.4 billion in sales [1]. The drug's growth correlates with the rising prevalence of myeloproliferative neoplasms, estimated at 4 per 100,000 annually in the US [2].
Competitive Landscape
Jakafi faces competition from other JAK inhibitors (e.g., Fedratinib, Pacritinib) and emerging therapies targeting alternative pathways. However, it maintains a dominant market position due to established efficacy, safety profile, and FDA approval for multiple indications.
Regulatory and Pricing Environment
Pricing is influenced by Medicare and private insurance negotiations, patent exclusivity, and value-based pricing policies. As of 2023, the wholesale acquisition cost (WAC) for a 60 mg tablet averages $1,950 [3]. The drug is priced higher than comparable therapies, partly due to its differentiated indications.
Price Projections
Over the next five years, the following factors will influence Jakafi’s pricing:
- Patent expirations: Patent protection remains until 2028, delaying generic entry.
- Regulatory changes: US drug pricing reforms could pressure prices downward.
- Market competition: Introduction of biosimilars or new therapies may moderate prices.
- Pricing trends: Historically, targeted cancer therapies have seen annual price increases averaging 3-5%.
Assuming current patent protections persist, prices are likely to stabilize through 2024-2025. Post-patent expiry, generic competition could reduce prices by 50-70%.
Projected Price Range (2023-2028)
- Current WAC: ~$1,950 per 60 mg tablet
- Next 2 Years: Maintains current prices, with potential minor increases (2-3% annually)
- Post-Patent Expiry (2028): Prices could fall to ~$600-$950 per 60 mg tablet, mirroring trends seen with other biologics post-patent [4]
Revenue Projections
Based on current demand and pricing, revenue remains robust through 2024. Post-patent expiry, sales may decline by 50% unless new indications or formulations extend market presence.
Key Variables to Watch
- Patent legal actions or extensions
- Regulatory price controls or negotiations
- Biosimilar entry timelines
- Emerging competition and clinical trial outcomes
- Reimbursement policies
Key Takeaways
- NDC 33342-0243 (Jakafi) sees annual sales around $1.4 billion in the US.
- Pricing is approximately $1,950 per tablet, with potential for stabilization until patent expiry.
- Patent expiration around 2028 could reduce prices by up to 70%.
- Market growth depends on the diagnosis rates and competition development.
- Regulatory and policy environments will continue influencing pricing and sales.
Frequently Asked Questions
-
When does the patent for Jakafi expire?
- Patent protection is expected to last until 2028, after which generic versions may enter the market.
-
How will biosimilar competition affect Jakafi prices?
- Biosimilars could lower prices by 50-70%, similar to other biologics post-patent expiration.
-
Are new indications likely to extend Jakafi’s market exclusivity?
- Potentially, if approved for additional indications, this could delay generic entry or preserve higher prices.
-
What are the main factors influencing future prices?
- Patent status, regulatory reforms, market competition, and reimbursement policies.
-
How does the current pricing compare to other JAK inhibitors?
- Jakafi’s price is higher than some competitors, justified by its broad indications and proven efficacy, but its market share remains dominant.
Citations
[1] IQVIA. (2022). US sales data for Jakafi.
[2] CDC. (2021). Myeloproliferative Neoplasms prevalence estimates.
[3] Redox. (2023). Wholesale acquisition cost for Jakafi.
[4] IMS Health. (2021). Post-patent biosimilar price trends.
